October 13, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Re: | Reviva Pharmaceuticals Holdings, Inc. |
Registration Statement on Form S-1 |
File No. 333-267762 |
Acceleration Request |
Requested Date: | October 17, 2022 |
Requested Time: | 4:00 p.m., Eastern Time |
Dear Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Steven Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely, | ||
REVIVA PHARMACEUTICALS HOLDINGS, INC. | ||
By: | /s/ Narayan Prabhu | |
Name: | Narayan Prabhu | |
Title: | Chief Financial Officer | |
